p70 S6‑Kinase: Recombinant Rabbit Monoclonal Antibody Tools for Dissecting the mTOR Signalling Hub

p70 S6‑Kinase as a Central Downstream Node within mTORC1‑Driven Signalling Networks

p70 S6‑Kinase belongs to the AGC‑family serine‑threonine kinase group and functions as one major effector molecule downstream of mTOR complex 1. Two distinct gene products, S6K1 and S6K2, share substantial sequence homology yet carry unique functional properties within cellular experimental systems. p70 S6‑Kinase phosphorylates ribosomal protein S6 plus other cellular substrates to modulate protein biosynthesis, cell‑cycle progression and metabolic phenotypes.

Full kinase activation requires coordinated input from mTORC1‑mediated phosphorylation events together with PI3K‑dependent signalling cascades. Multiple critical residues including Thr229 and Thr389 undergo phosphorylation to achieve complete catalytic‑domain activation. Aberrant hyper‑activation of this signalling axis appears in several tumour‑derived sample sets. S6K1 gene amplification and elevated protein abundance have been documented within breast, ovarian and gastric tumour‑model systems and correlate with negative prognostic readouts.

High‑quality antibody tools are essential to distinguish total p70 S6‑Kinase protein pools from phosphorylated activated fractions, and to resolve S6K1 versus S6K2 isoform abundance. Recombinant rabbit‑monoclonal‑antibody reagents support protein quantification, localization analysis and biochemical pull‑down experiments for mTOR‑pathway mechanistic investigation.

Critical Molecular Considerations for p70 S6‑Kinase Recombinant‑Antibody Development

The p70 S6‑Kinase polypeptide consists of N‑terminal, catalytic kinase and C‑terminal structural domains. Antibody development projects must define whether reagents target total‑protein epitopes or phosphorylation‑modified activation‑site epitopes. Pan‑protein antibodies typically bind conserved polypeptide stretches and suit western‑blot detection and immunoprecipitation workflows. Phospho‑specific clones require strict recognition of phosphorylated residues such as Thr389.

Distinct sequence features between S6K1 and S6K2 guide antigen selection for isoform‑selective antibody generation. Immunogens can consist of recombinant protein fragments or defined synthetic peptides covering individual domains or post‑translationally modified motifs. Rabbit immune repertoires can generate clones targeting conformational and modification‑dependent epitopes with appreciable binding affinity.

For immunohistochemistry applications using formalin‑fixed paraffin‑embedded tissue material, antibody clones must recognise epitopes stable after chemical cross‑linking procedures. Careful antigen design and multi‑platform screening help filter candidate clones suitable for mixed experimental workflows spanning biochemistry and histology.

Applications of Anti‑p70 S6‑Kinase Antibodies in Tumour‑Organoid‑Based Experimental Systems

Three‑dimensional tumour‑organoid culture systems preserve primary‑tumour tissue architecture and cellular heterogeneity, serving as valuable pre‑clinical research platforms. Recombinant anti‑p70 S6‑Kinase antibodies enable spatial profiling of mTOR‑pathway activation status across organoid micro‑regions via immunofluorescence imaging. Proliferative peripheral zones often display stronger S6 phosphorylation signals, whereas nutrient‑limited central compartments show dampened pathway activity.

During pharmacological intervention assays, these antibody reagents support quantitative measurement of phosphorylated‑S6 signal shifts after mTOR‑inhibitor or S6K‑targeted‑compound exposure. Researchers correlate target‑engagement readouts with organoid‑growth‑suppression phenotypic data. In gene‑edited organoid lines, antibodies validate S6K1 or S6K2 knockout efficiency and reveal potential compensatory signalling responses. When combined with immune‑cell marker antibodies, they help map crosstalk between tumour‑intrinsic mTOR signalling and surrounding immune microenvironment components.

Deciphering Signalling‑Network Dynamics and Supporting Pre‑Clinical Drug‑Discovery Workflows

Immunoprecipitation coupled with mass‑spectrometry using anti‑p70 S6‑Kinase antibodies permits identification of S6K‑associated multi‑protein complexes from cell lysate specimens. High‑resolution imaging tracks subcellular translocation events following insulin or growth‑factor stimulation, recording shifts toward plasma‑membrane and perinuclear compartments upon kinase activation. In acquired‑drug‑resistance model cell lines, antibodies detect pathway‑re‑activation events after sustained mTOR‑inhibitor treatment and expose bypass‑signalling mechanisms.

For small‑molecule‑inhibitor pre‑clinical evaluation, anti‑p70 S6‑Kinase reagents support phospho‑specific ELISA‑style assay construction to quantify target‑kinase functional suppression. Researchers correlate p70 S6‑Kinase and downstream S6 phosphorylation levels with cellular‑proliferation phenotypes in cell‑culture and organoid screening pipelines. Immunohistochemical staining of treated tumour tissue samples enables assessment of inhibitor magnitude and duration of target suppression within in‑vivo experimental settings. These detection tools also facilitate combinatorial‑drug‑screening projects by measuring additive signalling‑suppression effects from compound‑combination treatments.

Research‑Grade p70 S6 Kinase Antibody Reagent from ANT BIO PTE. LTD.

ANT BIO PTE. LTD. supplies p70 S6 Kinase Recombinant Rabbit mAb (clone S‑1278‑2, catalog S0B0875). This recombinant rabbit‑monoclonal antibody targets the conserved kinase domain of S6K1 encoded by RPS6KB1 gene. Validation datasets show low cross‑reactivity against S6K2 and other AGC‑family kinases such as Akt, PKC and RSK.

This antibody reagent has undergone experimental verification across western blot, immunoprecipitation, immunofluorescence, immunohistochemistry and flow‑cytometry workflows. Recombinant production technology sustains consistent performance across batches for long‑term serial laboratory projects. Full validation documentation including species‑reactivity profiles and multi‑application protocol suggestions is available for end‑user research‑project planning.

Related Product Portfolio

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.